©2010–2020 Apsis Therapeutics, Ltd. All rights reserved.
APSIS is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of HIV, Dengue, Zika, Ebola, HBV, HCV, Herpes simplex, and other viral infections. The Company is headquartered in Albany, New York, and began operations in 2010. APSIS develops effective antiviral agents based on our ntpLibraryTM, bcProtideTM and Cas9-lgRNATM discovery platform.
The APSIS business model aims to fill a void in the Pharmaceutical Industry’s new drug pipeline against multiple drug resistant viruses, latent or chronic viral infections, and newly emerging viral infectious diseases, and to prudently initiate partnerships for its discovery platform. We believe that our broadly-applicable technology will play a major role in life-enhancing, new product discoveries, enabling rapid and sustained growth for APSIS.
APSIS's efficient drug development platform generates more commercial opportunities than we can pursue independently. Strategic partnering is a critical component of our ability to advance APSIS's novel therapeutics programs into clinical development and onto the market. APSIS’s objective is to selectively license our technology and products with worldwide pharmaceutical companies at strategic stages of the development process while retaining selected therapeutic drugs to develop independently.